{
    "name": "belatacept",
    "comment": "Rx",
    "other_names": [
        "Nulojix"
    ],
    "classes": [
        "Immunosuppressants",
        "Selective T-Cell Costimulation Blockers"
    ],
    "source": "https://reference.medscape.com/drug/nulojix-belatacept-999204",
    "pregnancy": {
        "common": [
            "To monitor maternal-fetal outcomes of pregnant women who have received immunologics#immunosuppressants, healthcare providers are strongly encouraged to register pregnant patients in the Transplant Pregnancy Registry International (TPR) by calling 1-877-955-687",
            "There is insufficient data with belatacept use in pregnant women to inform on drug-associated risk"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Belatacept is known to cross the placenta of animals",
                    "Administration of belatacept to pregnant rats and rabbits during the period of organogenesis was not teratogenic at exposures approximately 16 and 19 times greater than that observed at the maximum recommended human dose (MRHD) of 10 mg/kg body weight administered over the first month of treatment, based on area under the concentration-time curve (AUC)",
                    "In a pre- and postnatal development study in rats, treatment-related infections in dams were associated with increased pup mortality, presumably secondary to deteriorating maternal health, at exposures 3 times higher than that observed at MRHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of belatacept in human milk or the effects of belatacept on breastfed infants or human milk production to inform risk of belatacept to an infant during lactation",
            "Belatacept is excreted in rat milk after IV administration, and it is possible that the drug will be present in human milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS)",
                "Recipients without immunity to Epstein-Barr virus (EBV) are at a particularly increased risk; therefore, use in EBV seropositive patients only",
                "Contraindicated in transplant recipients who are EBV seronegative or with unknown EBV serostatus",
                "Only physicians experienced in immunosuppressive therapy and management of kidney transplant patients should prescribe",
                "Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources",
                "The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient",
                "Increased susceptibility to infection and the possible development of malignancies may result from immunosuppression",
                "Not recommended for use in liver transplant patients because of increased risk of graft loss and death"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Patients who are EBV seronegative or with unknown EBV serostatus (see Black Box Warnings)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "See Black Box Warnings",
                "In postmarketing experience, use in conjunction with basiliximab induction, MMF, and corticosteroid minimization to 5 mg/day between Day 3 and Week 6 post-transplant was associated with an increased rate and grade of acute rejection, particularly Grade III rejection; these Grade III rejections occurred in patients with 4 to 6 HLA mismatches; graft loss was a consequence of Grade III rejection in some patients.",
                "Serious infection may occur including bacterial, viral (cytomegalovirus [CMV], herpes, polyoma virus nephropathy), fungal, and protozoal infections, including opportunistic infections (eg, tuberculosis); these infections may lead to serious, including fatal, outcomes",
                "Tuberculosis was more frequently observed",
                "Cases of polyoma virus-associated nephropathy (PVAN), mostly due to BK virus infection, reported",
                "Patients receiving immunologics#immunosuppressants, including belatacept, are in increased risk for developing malignancies; advised added precautions including limiting UV exposure and wearing sunscreen",
                "Risk of rejection with conversion from a calcineurin inhibitor (CNI) based maintenance regimen reported; conversion of stable kidney transplant recipients from a CNI based maintenance therapy to a belatacept based maintenance therapy not recommended unless the patient is CNI intolerant"
            ],
            "specific": [
                {
                    "type": "Post-transplant lymphoproliferative disorder",
                    "description": [
                        "Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the CNS, compared to patients on a cyclosporine-based regimen",
                        "As the total burden of immunosuppression is a risk factor for PTLD, higher than the recommended doses or more frequent dosing of belatacept and higher than recommended doses of concomitant immunosuppressive agents are not recommended",
                        "Consider PTLD in patients reporting new or worsening neurological, cognitive, or behavioral signs or symptoms",
                        "Risk of PTLD was higher in EBV seronegative patients compared to EBV seropositive patients",
                        "EBV seropositive patients are defined as having evidence of acquired immunity shown by the presence of IgG antibodies to viral capsid antigen (VCA) and EBV nuclear antigen (EBNA)",
                        "Epstein-Barr virus serology should be ascertained before starting administration of belatacept, and only patients who are EBV seropositive should receive belatacept",
                        "Transplant recipients who are EBV seronegative, or with unknown serostatus, should not receive belatacept (see Black Box Warnings and Contraindications)",
                        "Other known risk factors for PTLD include cytomegalovirus (CMV) infection and T-cell depleting therapy"
                    ]
                },
                {
                    "type": "Progressive multifocal leukoencephalopathy (PML)",
                    "description": [
                        "PML is a rare occurrence but is a rapidly progressive and fatal opportunistic infection of the CNS that is caused by the JC virus, a human polyoma virus",
                        "In clinical trials, 2 cases of PML were reported in patients receiving belatacept at higher cumulative doses and administered more frequently than the recommended regimen"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Avoid use of live vaccines during treatment with belatacept, including but not limited to the following: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines",
                        "In postmarketing experience in de novo kidney transplant recipients, venous thrombosis of the renal allograft reported when the initial dose of antithymocyte globulin (ATG), as immunosuppressive induction, was coadministered (at the same or nearly the same time) with the first dose of belatacept; coadministration of ATG and belatacept may pose a risk for venous thrombosis of the renal allograft; if ATG (or any other cell-depleting induction treatment) and belatacept will be administered concomitantly, consider a 12-hr interval between the 2 administrations",
                        "Monitor mycophenolate mofetil (MMF) dosage when a patientâ€™s therapy is switched between cyclosporine and belatacept; cyclosporine decreases mycophenolic acid (MPA) exposure by preventing enterohepatic recirculation of MPA while belatacept does not"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "belatacept, upadacitinib.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "belatacept, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "belatacept, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "belatacept, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "belatacept, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "belatacept decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "belatacept decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "belatacept, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "belatacept and sipuleucel-T both increase  immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Concomitant use of sipuleucel-T and immunosuppressives should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "belatacept, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "belatacept, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abatacept",
            "description": {
                "common": "belatacept and abatacept both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adalimumab",
            "description": {
                "common": "belatacept and adalimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "belatacept decreases effects of adenovirus types 4 and 7 live, oral by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alefacept",
            "description": {
                "common": "belatacept and alefacept both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alemtuzumab",
            "description": {
                "common": "belatacept and alemtuzumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anakinra",
            "description": {
                "common": "belatacept and anakinra both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "anthrax vaccine",
            "description": {
                "common": "belatacept decreases effects of anthrax vaccine by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithymocyte globulin equine",
            "description": {
                "common": "belatacept and antithymocyte globulin equine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "antithymocyte globulin rabbit",
            "description": {
                "common": "belatacept and antithymocyte globulin rabbit both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azacitidine",
            "description": {
                "common": "belatacept and azacitidine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "azathioprine",
            "description": {
                "common": "belatacept and azathioprine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "basiliximab",
            "description": {
                "common": "belatacept and basiliximab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "belatacept decreases effects of BCG vaccine live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belimumab",
            "description": {
                "common": "belatacept and belimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betamethasone",
            "description": {
                "common": "belatacept and betamethasone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "busulfan",
            "description": {
                "common": "belatacept and busulfan both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "belatacept and cabazitaxel both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "canakinumab",
            "description": {
                "common": "belatacept and canakinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capecitabine",
            "description": {
                "common": "belatacept and capecitabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carboplatin",
            "description": {
                "common": "belatacept and carboplatin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carmustine",
            "description": {
                "common": "belatacept and carmustine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "certolizumab pegol",
            "description": {
                "common": "belatacept and certolizumab pegol both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "belatacept and chlorambucil both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "belatacept decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "belatacept and cisplatin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cladribine",
            "description": {
                "common": "belatacept and cladribine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "belatacept and cortisone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "belatacept and cyclophosphamide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will decrease the level or effect of belatacept by  decreasing metabolism. Modify Therapy/Monitor Closely. Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when patient?s therapy is switched between cyclosporine and belatacept, "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cytarabine",
            "description": {
                "common": "belatacept and cytarabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "belatacept and dacarbazine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dactinomycin",
            "description": {
                "common": "belatacept and dactinomycin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daunorubicin",
            "description": {
                "common": "belatacept and daunorubicin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "belatacept decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "belatacept and denosumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "belatacept and dexamethasone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dichlorphenamide",
            "description": {
                "common": "dichlorphenamide and belatacept both decrease  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphtheria & tetanus toxoids",
            "description": {
                "common": "belatacept decreases effects of diphtheria & tetanus toxoids by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphtheria & tetanus toxoids/ acellular pertussis vaccine",
            "description": {
                "common": "belatacept decreases effects of diphtheria & tetanus toxoids/ acellular pertussis vaccine by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "docetaxel",
            "description": {
                "common": "belatacept and docetaxel both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "belatacept and doxorubicin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "belatacept and doxorubicin liposomal both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epirubicin",
            "description": {
                "common": "belatacept and epirubicin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etoposide",
            "description": {
                "common": "belatacept and etoposide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "everolimus",
            "description": {
                "common": "belatacept and everolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "belatacept and fingolimod both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "floxuridine",
            "description": {
                "common": "belatacept and floxuridine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludarabine",
            "description": {
                "common": "belatacept and fludarabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluorouracil",
            "description": {
                "common": "belatacept and fluorouracil both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemcitabine",
            "description": {
                "common": "belatacept and gemcitabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "golimumab",
            "description": {
                "common": "belatacept and golimumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "belatacept and hydrocortisone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "belatacept and hydroxyurea both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibritumomab tiuxetan",
            "description": {
                "common": "belatacept and ibritumomab tiuxetan both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idarubicin",
            "description": {
                "common": "belatacept and idarubicin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "belatacept and ifosfamide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "belatacept and imatinib both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "infliximab",
            "description": {
                "common": "belatacept and infliximab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "belatacept decreases effects of influenza A (H5N1) vaccine by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "belatacept decreases effects of influenza virus vaccine (H5N1), adjuvanted by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "belatacept decreases effects of influenza virus vaccine quadrivalent, intranasal by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "belatacept and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "leflunomide",
            "description": {
                "common": "belatacept and leflunomide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "belatacept and lomustine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "belatacept decreases effects of measles mumps and rubella vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "melphalan",
            "description": {
                "common": "belatacept and melphalan both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal A C Y and W-135 polysaccharide vaccine combined",
            "description": {
                "common": "belatacept decreases effects of meningococcal A C Y and W-135 polysaccharide vaccine combined by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "belatacept decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mercaptopurine",
            "description": {
                "common": "belatacept and mercaptopurine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methotrexate",
            "description": {
                "common": "belatacept and methotrexate both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "belatacept and methylprednisolone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitoxantrone",
            "description": {
                "common": "belatacept and mitoxantrone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "muromonab CD3",
            "description": {
                "common": "belatacept and muromonab CD3 both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mycophenolate",
            "description": {
                "common": "belatacept increases levels of mycophenolate by Other (see comment). Use Caution/Monitor. \nComment: Potential change of mycophenolic acid (MPA) exposure after crossover from cyclosporine to belatacept or from belatacept to cyclosporine in patients concomitantly receiving MMF."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "natalizumab",
            "description": {
                "common": "belatacept and natalizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelarabine",
            "description": {
                "common": "belatacept and nelarabine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ocrelizumab",
            "description": {
                "common": "belatacept and ocrelizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with high doses of corticosteroids is expected to increase the risk of immunosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab",
            "description": {
                "common": "belatacept and ofatumumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, belatacept.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "belatacept and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ozanimod",
            "description": {
                "common": "ozanimod, belatacept.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs in order to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "belatacept and paclitaxel both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "belatacept and paclitaxel protein bound both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentostatin",
            "description": {
                "common": "belatacept and pentostatin both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and belatacept both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pralatrexate",
            "description": {
                "common": "belatacept and pralatrexate both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "belatacept and prednisolone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "belatacept and prednisone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "belatacept and procarbazine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilonacept",
            "description": {
                "common": "belatacept and rilonacept both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab",
            "description": {
                "common": "belatacept and rituximab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rituximab-hyaluronidase",
            "description": {
                "common": "belatacept and rituximab-hyaluronidase both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "belatacept decreases effects of rotavirus oral vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and belatacept both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "belatacept decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "belatacept and sirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "belatacept decreases effects of smallpox (vaccinia) vaccine, live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "belatacept and tacrolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temozolomide",
            "description": {
                "common": "belatacept and temozolomide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "belatacept and temsirolimus both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teniposide",
            "description": {
                "common": "belatacept and teniposide both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioguanine",
            "description": {
                "common": "belatacept and thioguanine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiotepa",
            "description": {
                "common": "belatacept and thiotepa both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tocilizumab",
            "description": {
                "common": "belatacept and tocilizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topotecan",
            "description": {
                "common": "belatacept and topotecan both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tositumomab",
            "description": {
                "common": "belatacept and tositumomab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, belatacept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, belatacept.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "belatacept and triamcinolone acetonide injectable suspension both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "belatacept decreases effects of typhoid vaccine live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab and belatacept both increase  immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Owing to potential additive immunosuppressive effects, consider duration of effect and mechanism of action of these therapies if coadministered"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "belatacept and ustekinumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "belatacept decreases effects of varicella virus vaccine live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinblastine",
            "description": {
                "common": "belatacept and vinblastine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine",
            "description": {
                "common": "belatacept and vincristine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "belatacept and vincristine liposomal both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "belatacept and vinorelbine both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "belatacept decreases effects of yellow fever vaccine by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "belatacept decreases effects of zoster vaccine live by Other (see comment). Use Caution/Monitor. \nComment: The use of live vaccines should be avoided during treatment with belatacept. Inform patients that vaccinations may be less effective while they are being treated with belatacept."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine recombinant",
            "description": {
                "common": "belatacept decreases effects of zoster vaccine recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce the effectiveness of zoster vaccine recombinant."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Anemia",
            "percent": "45"
        },
        {
            "name": "Diarrhea",
            "percent": "39"
        },
        {
            "name": "Urinary tract infection",
            "percent": "37"
        },
        {
            "name": "Peripheral edema",
            "percent": "34"
        },
        {
            "name": "Constipation",
            "percent": "33"
        },
        {
            "name": "Hypertension",
            "percent": "32"
        },
        {
            "name": "Pyrexia",
            "percent": "28"
        },
        {
            "name": "Graft dysfunction",
            "percent": "25"
        },
        {
            "name": "Cough",
            "percent": "24"
        },
        {
            "name": "Nausea",
            "percent": "24"
        },
        {
            "name": "Vomiting",
            "percent": "22"
        },
        {
            "name": "Headache",
            "percent": "21"
        },
        {
            "name": "Hypokalemia",
            "percent": "21"
        },
        {
            "name": "Hyperkalemia",
            "percent": "20"
        },
        {
            "name": "Leukopenia",
            "percent": "20"
        },
        {
            "name": "Dyslipidemia",
            "percent": "19"
        },
        {
            "name": "Abdominal pain",
            "percent": "19"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "19"
        },
        {
            "name": "Hypotension",
            "percent": "18"
        },
        {
            "name": "Arthralgia",
            "percent": "17"
        },
        {
            "name": "Hyperglycemia",
            "percent": "16"
        },
        {
            "name": "Hematuria",
            "percent": "16"
        },
        {
            "name": "Proteinuria",
            "percent": "16"
        },
        {
            "name": "Blood creatinine increased",
            "percent": "15"
        },
        {
            "name": "Insomnia",
            "percent": "15"
        },
        {
            "name": "Upper respiratory infection",
            "percent": "15"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "13"
        },
        {
            "name": "Back pain",
            "percent": "13"
        },
        {
            "name": "Hypocalcemia",
            "percent": "13"
        },
        {
            "name": "CMV infection",
            "percent": "12"
        },
        {
            "name": "Dyspnea",
            "percent": "12"
        },
        {
            "name": "Influenza",
            "percent": "11"
        },
        {
            "name": "Dysuria",
            "percent": "11"
        },
        {
            "name": "Hypercholesterolemia",
            "percent": "11"
        },
        {
            "name": "Anxiety",
            "percent": "10"
        },
        {
            "name": "Bronchitis",
            "percent": "10"
        },
        {
            "name": "Renal tubular necrosis",
            "percent": "9"
        },
        {
            "name": "New onset diabetes",
            "percent": "8"
        },
        {
            "name": "Acne",
            "percent": "8"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "7"
        },
        {
            "name": "Hyperuricemia",
            "percent": "5"
        },
        {
            "name": "Venous thrombosis of the renal allograft when belatacept and antithymocyte coadministered at the same or nearly the same time",
            "percent": null
        },
        {
            "name": "Anaphylaxis",
            "percent": null
        }
    ]
}